MARKET

SLXNW

SLXNW

Silexion Therapeutics Corp
NASDAQ
0.0387
+0.0043
+12.50%
Closed 12:58 02/06 EST
OPEN
0.0387
PREV CLOSE
0.0344
HIGH
0.0387
LOW
0.0261
VOLUME
1.48K
TURNOVER
--
52 WEEK HIGH
0.1508
52 WEEK LOW
0.0200
MARKET CAP
--
P/E (TTM)
-0.0015
1D
5D
1M
3M
1Y
5Y
1D
Silexion Therapeutics unveils siRNA approach targeting KRAS mutations in pancreatic and other cancers
Reuters · 5d ago
Weekly Report: what happened at SLXNW last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at SLXNW last week (0119-0123)?
Weekly Report · 01/26 09:35
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
Reuters · 01/21 13:30
Weekly Report: what happened at SLXNW last week (0112-0116)?
Weekly Report · 01/19 09:38
Weekly Report: what happened at SLXNW last week (0105-0109)?
Weekly Report · 01/12 09:37
Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements
Reuters · 01/06 13:25
Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers
Reuters · 01/06 12:30
More
About SLXNW
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXNW stock methods without spending real money on the virtual paper trading platform.